Breastfeeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere).

Trial Profile

Breastfeeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere).

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine/zidovudine (Primary) ; Lopinavir/ritonavir (Primary) ; Nevirapine (Primary) ; Zidovudine (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms PROMISE-BF
  • Most Recent Events

    • 26 Jul 2017 Results of PROMISE 1077 BF/FF trial including (NCT01253538 and NCT01061151) related to hepatotoxicity in postpartum women initiating efavirenz presented at the 9th International AIDS Society Conference on HIV Science
    • 16 Feb 2017 Results of clinical risk factors for low birth weight and preterm delivery presented at the 24th Conference on Retroviruses and Opportunistic Infections
    • 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top